Mechanisms of extrahepatic vasodilation in portal hypertension

Gut

Volumn 57, Issue 9, 2008, Pages 1300-1314

  Hennenberg, M ^a   Trebicka, J ^a   Sauerbruch, T ^a   Heller, J ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; NITRIC OXIDE; VASODILATOR AGENT;

HUMAN; MUSCLE CONTRACTILITY; NONHUMAN; PHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ENDOCANNABINOIDS; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; SIGNAL TRANSDUCTION; SPLANCHNIC CIRCULATION; VASODILATION;

EID: 50249096895     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.144584     Document Type: Review

References (158)

1. Tsai MH. Splanchnic and systemic vasodilation. The patient. J Clin Gastroenterol 2007;41:S266-71.
2. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
3. Knotek M, Rogachev B, Schrier RW. Update on peripheral arterial vasodilation, ascites and hepatorenal syndrome in cirrhosis. Can J Gastroenterol 2000;14(Suppl D):112D-21D.
4. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-8.
5. Moller S, Henriksen J. The systemic circulation in cirrhosis. In: Gines P, Arroyo V, Rodes J, Schrier RW, eds. Ascites and renal dysfunction in liver disease. 2nd edn. Oxford: Blackwell Publishing, 2005:139-155.
6. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-95.
7. 2-adrenoceptors and plasma catecholamines in patients with cirrhosis. Gastroenterology 1992;102:2015-23.
8. Henriksen JH, Ring-Larsen H, Kanstrup IL, et al. Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence for enhanced sympathetic nervous activity in patients with decompensated cirrhosis. Gut 1984;25:1034-43.
9. Nicholls KM, Shapiro MD, Van Putten YJ, et al. Elevated plasma norepinephrine concentrations in decompensated cirrhosis: association with increased secretion rates, normal clearance rates and suppressibility by central volume expansion. Circ Res 1985;56:457-61.
10. Ma Z, Lee SS. Cirrhotic cardiomyopathie: getting to the heart of the matter. Hepatology 1996;24:451-9.
11. Pateron D, Oberti F, Lefilliatre P, et al. Relationship between vascular reactivity in vitro and blood flows in rats with cirrhosis. Clin Sci (Lond) 1999;97:313-8.
12. Geerts AM, De Vriese AS, Vanheule E, et al. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. Liver Int 2006;26:889-98.
13. Pfitzer G. Regulation of myosin phosphorylation in smooth muscle. J Appl Physiol 2001;91:497-503.
14. Somlyo AP, Wu X, Walker LA, et al. Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Rev Physiol Biochem Pharmacol 1999;134:201-34.
15. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 2000;522:177-85.
16. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003;83:1325-58.
17. Feil R, Lohmann SM, de Jonge H, et al. Cyclic GMP-dependent protein kinases and the cardiovascular system. Circ Res 2003;93:907-16.
18. Hofmann F, Ammendola A, Schlossmann J. Rising behind NO: cGMP-dependent protein kinases. J Cell Sci 2000;113:1671-6.
19. Münzel T, Feil R, Mülsch A, et al. Physiology and pathophysiology of vascular signaling controlled by cyclic guanosine 3′, 5′-cyclic monophosphate-dependent protein kinase. Circulation 2003;108:2172-83.
20. Sausbier M, Schubert R Voigt, Hirneiss C, et al. Mechanisms of NO/cGMP-mediated vasorelaxation. Circ Res 2000;87:825-30.
21. Hennenberg M, Biecker E, Trebicka J, et al. Defective RhoA/ Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006;130:838-54.
22. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-4.
23. Kimura M, Kimura I, Kobayashi S. Relationship between cyclic AMP-dependent protein kinase activation and Ca uptake increase of sarcoplasmic reticulum fraction of hog biliary muscles relaxed by cholecystokinin-C-terminal peptides. Biochem Pharmacol 1982;31:3077-83.
24. 2+ influx in vascular smooth muscle cells. Hypertension 1996;27:774-80.
25. Sessa WC. eNOS at a glance. J Cell Sci 2004;117: 2427-9.
26. Potter LR, Hunter T. Guanylyl cyclase-linked natriuretic peptide receptors: structure and regulation. J Biol Chem 2001;276:6057-60.
27. Albornoz L, Motta A, Alvarez D, et al. Nitric oxide synthase activity in the splanchnic vasculature of patients with cirrhosis: relationship with hemodynamic disturbances. J Hepatol 2001;35:452-6.
28. Heller J, Kristeleit H, Brensing KA, et al. Nitrite and nitrate levels in patients with cirrhosis of the liver: influence of kidney function and fasting state. Scand J Gastroenterol 1999;34:297-302.
29. Kirstetter P, Moreau R, Vachiery F, et al. Plasma concentrations of cyclic 3′, 5′-guanosine monophosphate in patients with cirrhosis: relationship with atrial natriuretic peptide and haemodynamics. J Gastroenterol Hepatol 1997;12:233-6.
30. Kimpel M, Folz IC, Hanisch E. Time course-dependent evolution of nitric oxide-mediated arterial hyporeactivity to phenylephrine in rats with ligated bile duct. Scand J Gastroenterol 1998;33:314-8.
31. Claria J, Jimenez W, Ros J, et al. Increased nitric oxide-dependent vasorelaxation in aortic rings of cirrhotic rats with ascites. Hepatology 1994;20:1615-21.
32. Niederberger M, Martin PY, Gines P, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995;109:1624-30.
33. Huang YT, Lo JW, Lin HC, et al. Change in vascular cAMP and cGMP contents in portal hypertensive rats. Pharmacology 1995;50:86-91.
34. Lee FY, Albillos A, Colombato LA, et al. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992;16:1043-8.
35. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol 1992;262:G996-1001.
36. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992;103:235-9.
37. Stumm MM, D'Orazio D, Sumanovski LT, et al. Endothelial, but not the inducible, nitric oxide synthase is detectable in normal and portal hypertensive rats. Liver 2002;22:441-50.
38. Tazi KA, Barriere E, Moreau R, et al. Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis. Gastroenterology 2002;122:1869-77.
39. Martin PY, Xu DL, Niederberger M, et al. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol 1996;270:F494-9.
40. Morales-Ruiz M, Jimenez W, Perez-Sala D, et al. Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology 1996;24:1481-6.
41. Niederberger M, Gines P, Martin PY, et al. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Hepatology 1996;24:947-51.
42. Weigert AL, Martin PY, Niederberger M, et al. Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. Hepatology 1995;22:1856-62.
43. Heller J, Sogni P, Tazi KA, et al. Abnormal regulation of aortic NOS2 and NOS3 activity and expression from portal vein-stenosed rats after lipopolysaccharide administration. Hepatology 1999;30:698- 704.
44. Wiest R, Shah V, Sessa WC. et al. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999;276:G1043-51.
45. Gadano AC, Sogni P, Heller J, et al. Vascular nitric oxide production during the development of two experimental models of portal hypertension. J Hepatol 1999;30:896-903.
46. Sogni P, Smith AP, Gadano A, et al. Induction of nitric oxide synthase II does not account for excess vascular nitric oxide production in experimental cirrhosis. J Hepatol 1997;26:1120-7.
47. Aller MA, Vara E, Garcia C, et al. Proinflammatory liver and antiinflammatory intestinal mediators involved in portal hypertensive rats. Mediators Inflamm 2005;(2):101-111.
48. Chu CJ, Lee FY, Wang SS, et al. Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumor necrosis factor-alpha and nitric oxide. Clin Sci (Lond) 1997:219-25.
49. Tazi K, Moreau R, Herve P, et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology 2005;129:303-14.
50. Tazi KA, Quioc JJ, Saada V, et al. Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J Hepatol 2006;45:280-289.
51. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rat stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999;104:1223-33.
52. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995;108:761-7.
53. Lopez-Talavera JC, Cadelina G, Olchowski J, et al. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996;23:1616-21.
54. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006;130:1886-900.
55. Hori N, Wiest R, Groszmann RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology 1998;28:1467-73.
56. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003;284:R1-12.
57. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001;299:818-24.
58. Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399:601-5.
59. Iwakiri Y, Tsai MH, McCabe TJ, et al. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol 2002;282:H2084-90.
60. + channels in in vitro nitric oxide-mediated aortic hyporeactivity to α-adrenergic vasoconstriction in rats with cirrhosis. J Hepatol 2001;35:350-7.
61. Abraldes JG, Iwakiri Y, Loureiro-Silva M, et al. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 2006;290:G980-7.
62. Tsai MH, Iwakiri Y, Cadelina G, et al. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 2003;125:1452-61.
63. Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology 1992;15:323-8.
64. Wiest R, Cadelina G, Milstien S, et al. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology 2003;38:1508-15.
65. Rasaratnam B, Kaye D, Jennings G, et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003;139:186-93.
66. Ai JH, Yang Z, Qiu FZ, et al. Heat shock protein 90 is responsible for hyperdynamic circulation in portal hypertensive rats. World J Gastroenterol 2003;9:2544-7.
67. Shah V, Wiest R, Garcia-Cardena G, et al. Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol 1999;277:G463-8.
68. Laleman W, Omasta A, Van de Casteete M. et al. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology 2005;42:1382-90.
69. Uuch P, Torondel B, Medina P, et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol 2004;41:55-9:
70. Jurzik L, Froh M, Straub RH, et al. Up-regulation of nNOS and associated increase in nitrergic vasodilation in superior mesenteric arteries in pre-hepatic portal hypertension. J Hepatol 2005;43:258-65.
71. Sieber CC, Sumanovski LT. Moll-Kaufmann C, et al. Hyposensitivity to nerve stimulation in portal hypertensive rats: role of nitric oxide. Eur J Clin Invest 1997;27:902-7.
72. Wanstall JC, Homer KL, Doggrell SA. Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets. Curr Vasc Pharmacol 2005;3:41-53.
73. 2+-sensitivity and cGMP-independent effects of NO in vascular smooth muscle. Nitric Oxide 2005;12:105-13.
74. Soloviev A, Lenen'kyi V, Zelensky S, et al. Nitric oxide relaxes rat tail artery smooth muscle by cyclic GMP-independent decrease in calcium sensitivity of myofilaments. Cell Calcium 2004;36:165-73.
75. Atucha NM, Ortiz MC, Fortepiani LA, et al. Role of cyclic guanosine monophosphate and K+ channels as mediators of the mesenteric vascular hyporesponsiveness in portal hypertensive rats. Hepatology 1998;27:900-5.
76. Ros J, Claria J, To-Figueras J. et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat Gastroenterology 2002;122:85-93.
77. Domenicali M, Ros J, Fernandez-Varo G. et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut 2005;54:522-7.
78. Randall MD, Kendall DA, O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 2004,142:20-6.
79. Moezi L, Gaskari SA, Liu H, et al. Anandamide mediates hyperdynamic circulation in cirrhotic rats via C8(1) and VR(1) receptors. Br J Pharmacol 2006;149:898-908.
80. Batkai S, Jarai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001;7:827-32.
81. Fernandez-Rodriguez CM, Romero J. Petros TJ, ef al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int 2004;24:477-83.
82. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004;84:903-34.
83. Fabrega E, Casafont F. Crespo J, et al. Plasma adrenomedullin levels in patients with hepatic cirrhosis. Am J Gastroenterol 1997;92:1901-4.
84. Farnandez-Rodriguez CM, Prada IR, Prieto J, et al. Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. J Hepatol 1998;29:250-6.
85. Ganesca J, Gonzalez A, Catalan R, et al. Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. Dig Dis Sci 1999;44:372-6.
86. Guevara M, Gines P. Jimenez W, et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998;114:336-43.
87. Kojian H, Sakurai S, Uemura M. et al. Adrenomedullin contributes to vascular hyporeactivity in cirrhotic rats with ascites via release of nitric oxide. Scand J Gastroenterol 2004;7:686-93.
88. Sakurai S, Kojima H, Uemura M, et al. Local regulator adrenomedullin contributes to the circulatory disturbance in cirrhotic rats. World J Gastroenterol 2006;12:2095-102.
89. Tahan V, Avsar E, Karaca C, et al. Adrenomedullin in cirrhotic and non-cirrhotic portal hypertension. World J Gastroenterol 2003;9:2325-7.
90. Fernandez Rodriguez C, Prieto J. Quiroga J, et al. Atrial natriuretic factor in cirrhosis: relationship to renal function and hemodynamic changes. J Hepatol 1994;21:211-6.
91. Montoliu C, Kosenko E, Del Olmo JA, et al. Correlation of nitric oxide and atrial natriuretic peptide changes with altered cGMP homeostasis in liver cirrhosis. Liver Int 2005;25:787-95.
92. Hou MC, Cahill PA. Zhang S, et al. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology 1998;27:20-7.
93. Potenza MA, Botrugno OA, De Salvia MA, et al. Endothelial COX-1 and -2 differentially affect reactivity of MVB in portal hypertensive rats. Am J Physiol Gastrointest Liver Physiol 2002;283:G587-94.
94. Oberti F, Sogni P, Cailmail S, et al. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension. Hepatology 1993;18:621-7.
95. Jeremy JY, Mikhailidis DP, Karatapanis S, et al. Altered prostacyclin synthesis by aortae from hepatic portal vein-constricted rats: evidence for effects on protein kinase C and calcium. J Hepatol 1994;21:1017-22.
96. Cahill PA, Wu Y, Sitzmann JV. Altered adenylyl cyclase activities and G-protein abnormalities in portal hypertensive rabbits. J Clin Invest 1994;93:2691-700.
97. Chen YC, Gines P, Yang J, et al. Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. Hepatology 2004;39:1075-87.
98. Bolognesi M, Sacerdoti D, Di Pascoli M, et al. Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with cirrhosis. Gut 2005;54:1630-6.
99. Sacerdoti D, Abraham NG, Oyekan AO, et al. Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats. J Pharmacol Exp Ther 2004;308:636-43.
100. Erario MA, Gonzales S, Romay S, et al. Role of heme oxygenase/ carbon monoxide pathway on the vascular response to noradrenaline in portal hypertensive rats. Clin Exp Pharmacol Physiol 2005;32:196- 201.
101. Kharitonov VG, Sharma VS, Pilz RB, et al. Basis of guanylate cyclase activation by carbon monoxide. Proc Natl Acad Sci USA 1995 28;92:2568-71.
102. Stone JR, Marletta MA. Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry 1994;33:5636-40.
103. Koglin M, Behrends S. Biliverdin IX is an endogenous inhibitor of soluble guanylyl cyclase. Biochem Pharmacol 2002;64:109-16.
104. Moreau R, Komeichi H, Kirstetter P, et al. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994;106:1016-23.
105. Lahaye P, Fouassier L, Tazi KA, et al. Endothelium- dependent blunted membrane potential responses to ATP-sensitive K+ channel modulators in aortae from rats with cirrhosis. J Hepatol 1999;30:107-14.
106. Moreau R, Komeichi H, Cailmail S, et al. Blockade of ATP-sensitive potassium channels by glibenclamide reduces portal pressure and hyperdynamic circulation in portal hypertensive rats. J Hepatol 1992;16:215-8.
107. Atucha NM, Ortiz MC, Fortepiani LA, et al. Mesenteric hyporesponsiveness in cirrhotic rats with ascites: role of cGMP and K+ channels. Clin Science 2000;99:455-60.
108. Lowicka E Beltowski. Hydrogen sufide (H2S)-the third gas of interest for pharmacologists. Pharmacol Rep 2007;59:4-24.
109. Ebrahimkhani MR, Mani AR, Moore K. Hydrogen sulphide and the hyperdynamic circulation in cirrhosis: a hypothesis. Gut 2005;54:1668-71.
110. Iwakiri Y. The molecules: mechanisms of arterial vasodilation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol 2007;41 :S288-94.
111. Barriere E, Tazi KA, Rona JP, et al. Evidence for an endothelium-derived hyperpolarizing factor in the superior mesenteric artery from rats with cirrhosis. Hepatology 2000;32:935-41.
112. Ferraz JG, McKnight W, Sharkey KA, et al. Impaired vasodilatory responses in the gastric microcirculation of anesthezized rats with secondary biliary cirrhosis. Gastroenterology 1995;108:1183-91.
113. Lee SS, Chilton EL, Pak JM. Adenosine receptor blockade reduces splanchnic hyperemia in cirrhotic rats. Hepatology 1992;15:1107- 11.
114. de Brito MT, Canto A, Correia JH, et al. Adenosine A(2A) receptors in portal hypertension: their role in the abnormal response to adenosine of the cranial mesenteric artery in rabbits. Br J Pharmacol 2002;135:1324-30.
115. Murakami S, Bernardo JF, Branch RA, et al. Adenosine does not mediate renal sodium retention and peripheral vasodilation elicited by partial portal vein ligation in rats. Hepatology 1996;23:346-52.
116. Champigneulle B, Braillon A, Kleber G, et al. Adenosine and hemodynamic alterations in cirrhotic rats. Am J Physiol 1991;260:G543-7.
117. Colle IO, De Vriese AS, Van Vlierberghe HR, et al. Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension: an in-vivo study. Eur J Gastroenterol Hepatol 2004;16:139-45.
118. Hartleb M, Moreau R, Cailmail S, et al. Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis. Gastroenterology 1994;107:1085-93.
119. Heinemann A, Wachter CH, Holzer P, et al. Nitric oxide-dependent and -independent vascular hyporeactivity in mesenteric arteries of portal hypertensive rats. Br J Pharmacol 1997;121:1031-7.
120. Heller J, Trebicka J, Shiozawa T, et al. Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. Liver Int 2005;25:657-66.
121. Hennenberg M, Trebicka J, Biecker E, et al. Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology 2007;45:495-506.
122. Karatapanis S, McCormick PA, Kakad S, et al. Alteration in vascular reactivity in isolated aortic rings from portal vein-constricted rats. Hepatology 1994;20:1516-21.
123. Lin HC, Yang YY, Huang YT, et al. Vascular contractile response and signal transduction in endothelium-denuded aorta from cirrhotic rats. World J Gastroenterol 2005;11:2306-12.
124. Mathie RT, Ralevic V, Moore KP, et al. Mesenteric vasodilator response in cirrhotic rats: a role for nitric oxide? Hepatology 1996;23:130-6.
125. Ortiz MC, Fortepiani LA, Martinez C, et al. Vascular hyporesponsiveness in aortic rings from cirrhotic rats: role of nitric oxide and endothelium. Clin Sci (Lond) 1996;91:733-8.
126. Robert R, Chagneau-Derrode C, Carretier M, et al. Gender differences in vascular reactivity of aortas from rats with and without portal hypertension. J Gastroenterol Hepatol 2005;20:890-4.
127. Heller J, Schepke M, Gehnen N, et al. Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology 1999;116:387-93.
128. Islam MZ, Williams BC Madhavan K, et al. Selective alteration of agonist-mediated contraction in hepatic arteries isolated from patients with cirrhosis. Gastroenterology 2000;118:765-71.
129. Schepke M, Heller J, Paschke S, et al. Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: evidence for a receptor-specific mechanism. Hepatology 2001;34:884-8.
130. Angeli P, Fernandez-Varo G, Dalla Libera V, et al. The role of nitric oxide in the pathogenesis of systemic and splanchnic vasodilation in cirrhotic rats before and after the onset of ascites. Liver Int 2005;25:429-37.
131. Garcia-Pagan JC, Fernandez M, Bernadich C, et al. Effects of continued NO inhibition on portal hypertensive syndrome after portal vein stenosis in rat. Am J Physiol 1994;267:G984-90.
132. Helmy A, Newby DE, Jalan R, et al. Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut 2003;52:410-5.
133. Iwakiri Y, Cadelina G, Sessa WC, et al. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Gastrointest Liver Physiol 2002;283:G1074-081.
134. Koshy A, De Gottardi A, Ledermann M, et al. Endothelial nitric oxide synthase is not essential for the development of fibrosis and portal hypertension in bile duct ligated mice. Liver Int 2005;25:1044-52.
135. Theodorakis NG, Wang YN, Skill NJ, et al. The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: studies in gene-knockout mice. Gastroenterology 2003;124:1500-8.
136. Hartleb M, Moreau R, Gaudin C, et al. Lack of vascular hyporesponsiveness to the L-type calcium channel activator, Bay K 8644, in rats with cirrhosis. J Hepatol 1995;22:202-7.
137. Neef M, Biecker E, Heller J, et al. Portal hypertension is associated with increased mRNA levels of vasopressor G-protein-coupled receptors in human hepatic arteries. Eur J Clin Invest 2003;33:249-55.
138. Gaudin C, Launay JM, Moreau R, et al. Discrepant regulation among alpha and beta adrenoceptors in vascular walls of cirrhotic rats [abstract]. J Hepatol 1994;21:S43.
139. Liao JF, Yu PC, Lin HC, et al. Study on the vascular reactivity and alpha 1-adrenoceptors of portal hypertensive rats. Br J Pharmacol 1994;111:439-44.
140. Tazi KA, Moreau R, Heller J, et al. Changes in protein kinase C isoforms in association with vascular hyporeactivity in cirrhotic rat aortas. Gastroenterology 2000;119:201-10.
141. Trombino C, Tazi KA, Gadano A, et al. Protein kinase C alterations in aortic vascular smooth muscle cells from rats with cirrhosis. J Hepatol 1998;28:670-6.
142. Böhm SK, Grady EF, Bunnett NW. Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem J 1997;322:1-18.
143. Bünemann M, Hosey MM. G-protein coupled receptor kinases as modulators of G-protein signalling. J Physiol 1999;517:5-23.
144. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001;53:1-24.
145. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002;115:455-65.
146. Shenoy SK, Lefkowitz RJ. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 2003;375:503-15.
147. Thomas WG, Qian H. Arresting angiotensin type 1 receptors. Trends Endocrin Metabol 2003;14:130-6.
148. Willets JM, Challiss RAJ, Nahorski SR. Non-visual GRKs: are we seeing the whole picture? Trends Pharmacol Sci 2003;24:626-33.
149. Zhang HY, Shirasawa Y, Chen X, et al. Impaired agonist-dependent myosin phosphorylation and decreased RhoA in rat portal hypertensive mesenteric vasculature. Am J Physiol Gastrointest Liver Physiol 2005;288:G603-8.
150. Trebicka J, Leifeld L, Hennenberg M, et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 2007;47:1264-76.
151. Zhou O. Hennenberg M. Trebicka J, et al. Intrahepatic upregulation of RhoA and Rho-Kinase signaling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006;55:1296-305.
152. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by β-arrestins. Science 2005;308:512-7.
153. McDonald PH. Lefkowitz RJ. βArrestins: new roles in regulating heptahelical receptors' functions. Cell Signal 2001;13:683-9.
154. Miller WE. Lefkowitz RJ. Expanding roles for β-arrestins as scaffolds and adapters in GPCR signaling and trafficking. Curr Op Cell Biol 2001;13:139-45.
155. Pawlak G, Helfman DM. Post-transcriptional down-regulation of ROCKI/Rho-kinase through an MEK-dependent pathway leads to cytoskeleton disruption in Ras-transformed fibroblasts. Mol Biol Cell 2002;13:336-47.
156. Wiest R. Jurzik L, Herold T,et al. Rote of NPY for vasoregutation in the splanchnic circulation during portal hypertension. Peptides 2007;28:396-404.
157. Wiest R, Jurzik L, Moleda L, et al. Enhanced Y1-receptor-mediated vasoconstrictive action of the neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. J Hepatol 2006;44:512-9.
158. Uriz J, Gines P, Ortega R, et al. Increased plasma levels of neuropeptide Y in hepatorenal syndrome. J Hepatol 2002;36:349- 55.